Prescient Therapeutics: Ledger

Investor	Rounds	Invested
No investors recorded yet. Know one?

Company	Kind	Announced	Price	Sources
Prescient Therapeutics is not recorded as having acquired anything.

Name	Role	Sources
Steven Yatomi-Clarke	Chief Executive	Wholesale Investor

19 deals

Cap Raise Crucible: Canaccord leads big mining dash for cash

Roundup of 35 ASX capital raisings seeking a combined $687.5m in late August and early September, led by mining deals; Canaccord Genuity topped the broker table and three IPOs floated.

The Age Business Fri 11 Sep 2026 Alliance Aviation Services Andean Silver Black Bear Minerals Broken Hill Mines Castle Minerals Core Energy Minerals Critical Resources Duxton Farms Eureka Group Holdings Falcon Metals FireFly Metals Jameson Resources Mount Ridley Mines PC Gold Prescient Therapeutics Sierra Nevada Gold Titomic West Coast Silver WIN Metals 4DS Memory 62 Capital 708 Capital Pty Ltd Adriatic Metals Almasar Minerals Argonaut Securities Pty Limited Axiant Resources BMO Nesbitt Burns Bulls N' Bears CIBC World Markets CPS Capital Fosters Stockbroking Hannam & Partners Jenesys JP Equity Holdings Moelis Australia Morgans Corporate Oracle Capital Group PAC Partners Pamplona Capital Powerhaus Uranium RBC Dominion Securities Unified Capital Partners Wallabi Group Alpine Capital Barrenjoey Markets Bell Potter Blue Ocean Equities Canaccord Genuity Euroz Hartleys Limited Jett Capital Advisors Peloton Capital Petra Capital Paul Cronin Eric DeMori Jason Skinner

23 deals

Cap Raise Crucible: Canaccord leads big mining dash for cash

Roundup tallies 35 ASX equity fundraises seeking $687.5 million, mostly miners; Canaccord Genuity led broker mandates with nine deals, while FireFly Metals' $190 million package was the period's largest.

SMH Business Fri 11 Sep 2026 4DS Memory Alliance Aviation Services Almasar Minerals Andean Silver Axiant Resources Black Bear Minerals Broken Hill Mines Castle Minerals Core Energy Minerals Critical Resources Duxton Farms Eureka Group Holdings Falcon Metals FireFly Metals Jameson Resources Mount Ridley Mines PC Gold Powerhaus Uranium Prescient Therapeutics Sierra Nevada Gold Titomic West Coast Silver WIN Metals Adriatic Metals Bulls N' Bears Jenesys 62 Capital 708 Capital Pty Ltd Alpine Capital Argonaut Securities Pty Limited Barrenjoey Markets Bell Potter Blue Ocean Equities BMO Nesbitt Burns Canaccord Genuity CIBC World Markets CPS Capital Euroz Hartleys Limited Fosters Stockbroking Hannam & Partners Jett Capital Advisors JP Equity Holdings Moelis Australia Morgans Corporate Oracle Capital Group PAC Partners Pamplona Capital Peloton Capital Petra Capital RBC Dominion Securities Unified Capital Partners Wallabi Group Paul Cronin Eric DeMori Jason Skinner

Also The Age Business

Exit / M&A

Manufacturing news briefs – stories you may have missed

@AuManufacturing Mon 16 Dec 2019 1414 Prescient Therapeutics Shell

Exit / M&A

Prescient Therapeutics bringing new ‘basket’ approach to cancer trials

Profile of Australian cancer drug developer Prescient Therapeutics, whose basket-trial strategy echoes Loxo Oncology, acquired earlier in 2019 for US$8 billion.

Wholesale Investor Thu 11 Apr 2019 Prescient Therapeutics Steven Yatomi-Clarke

Prescient Therapeutics

Funding history

Investors

What Prescient Therapeutics bought

People

Coverage

Cap Raise Crucible: Canaccord leads big mining dash for cash

Cap Raise Crucible: Canaccord leads big mining dash for cash

Manufacturing news briefs – stories you may have missed

Prescient Therapeutics bringing new ‘basket’ approach to cancer trials